There is increasing evidence that FLT3-ITD has activity in hematopoietic stem cells (37), as demonstrated by the presence of ITD in the CD34+CD38− leukemia-initiating cell (LIC) population, and confirmation of the ITD mutation in these successfully engrafted LICs in a murine transplant model (38). Here, CD34 is linked to leukemia.